Kymera Therapeutics 2024年Q4 GAAP每股收益$(0.88)不及预期$(0.78),销售额$739万不及预期$1182万

财报速递02-27
Kymera Therapeutics(NASDAQ:KYMR)报告季度每股亏损$(0.88),比分析师的共识预期$(0.78)低12.82%。与去年同期每股亏损$(0.25)相比,这是252%的下降。公司报告季度销售额为739万美元,比分析师的共识预期1182万美元低37.45%。与去年同期销售额4788万美元相比,这是84.56%的下降。

以上内容来自Benzinga Earnings专栏,原文如下:

Kymera Therapeutics (NASDAQ:KYMR) reported quarterly losses of $(0.88) per share which missed the analyst consensus estimate of $(0.78) by 12.82 percent. This is a 252 percent decrease over losses of $(0.25) per share from the same period last year. The company reported quarterly sales of $7.39 million which missed the analyst consensus estimate of $11.82 million by 37.45 percent. This is a 84.56 percent decrease over sales of $47.88 million the same period last year.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白
发表看法